Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
The New Trade Policy for America – How Will It Affect Korea? Mike Palmedo Research Coordinator Program on Information Justice and Intellectual Property Washington College of Law, American University June 4, 2006 - Seoul, Republic of Korea May 10, 2007: New Trade Policy Announced “Today we have seized an historic opportunity to restore the bipartisan consensus on trade with a clear and reasonable path forward for congressional consideration of Free Trade Agreements with Peru, Colombia, Panama and Korea. - USTR Susan Schwab Labor Chapter of the New Trade Policy for America An enforceable commitment that FTA countries will adopt the in their laws and practice the five basic international labor standards, as stated in the 1998 International Labor Organization Declaration. Binding commitment prohibiting FTA countries from lowering labor standards. Same dispute settlement mechanisms and penalties as other FTA obligations. Environmental Chapter of the New Trade Policy for America A fully enforceable commitment that FTA countries adopt, implement and enforce in their laws and practice obligations under seven common major multilateral environmental agreements. A binding commitment prohibiting FTA countries from lowering environmental standards. Same dispute settlement mechanisms and penalties as other FTA obligations. A "conflict of laws" provision, where environmental treaty obligations trump FTA obligations when the two conflict. IPR Chapter of the New Trade Policy for America Though portrayed in the media as a compromise, language on access to medicines still TRIPS-Plus. The intellectual property section is meant to increase access to medicines in “developing countries.” It is meant for the FTAs with Peru, Panama, and Colombia. Korus FTA & New Trade Policy for America’s IP Guidelines “Most of the IP provisions do not apply to the Korus FTA. The one provision that would apply is point 3(d).” - Ways and Means Staff May 29, 2007 Data Exclusivity New Trade Policy Korus FTA Five year period of data exclusivity for New Chemical Entities. Concurrent periods of exclusivity if approval in one nation is based on approval in another Five year period of data exclusivity for New Chemical Entities. Three year period of data exclusivity for drugs that are not NCEs, but required clinical testing for approval. Non-concurrent periods of exclusivity if approval in one nation is based on approval in another “Linkage” New Trade Policy Korus FTA “No requirement that the drug regulatory agency withhold approval of a generic until it can certify that no patent would be violated if the generic were marketed.” Parties must “implement measures in its marketing approval process to prevent… other persons from marketing a product without the consent or acquiescence of the patent owner during the term of a patent.” Patent Extensions New Trade Policy Korus FTA Parties “may” include Parties “shall” patent extensions to include patent make up for delays in extensions to make the granting of either up for delays in the a patent or marketing granting of either a approval. patent or marketing approval. Second Use Patents New Trade Policy Korus FTA Second use patents not covered. Second use patents mandatory. Pharmaceuticals Chapter Favors Brand Name Firms When determining reimbursement, authorities must "appropriately recognize the value of patented pharmaceutical products and medical devices." Pharmaceutical firms may appeal any decision not to include their products on the positive list for reimbursement. Korus FTA mandates a burdensome process for the negotiation of the reimbursement rate for each drug. Three Things to Remember The New Trade Policy for America does not apply to the intellectual property chapter of the Korus FTA. The Korus FTA intellectual property chapter will delay generic competition. The Pharmaceuticals and Medical Devices Chapter will encourage the Korean National Health Insurance to favor expensive, brandname drugs. wcl.american.edu/pijip